Liu, L., Y. Wu, K. Ye, M. Cai, G. Zhuang and J. Wang (2022). "Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking." Frontiers in Pharmacology 13. Download PDF Qi, X., F. Li, Y. Wu, C. Cheng, P. Han, J. Wang and X. Yang (2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity." Nature Communications 10(1): 2141. Download PDF
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.